HC
REGN icon

HNP Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

HNP Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$919K Sell
1,118
-24
-2% -$18.1K 0.26% 79
2022
Q4 		$824K Sell
1,142
-31
-3% -$22.9K 0.23% 83
2022
Q3 		$808K Sell
1,173
-21
-2% -$13.2K 0.23% 79
2022
Q2 		$706K Sell
1,194
-25
-2% -$16.3K 0.19% 93
2022
Q1 		$851K Sell
1,219
-60
-5% -$38K 0.2% 91
2021
Q4 		$808K Buy
1,279
+37
+3% +$22.7K 0.18% 97
2021
Q3 		$752K Buy
1,242
+30
+2% +$18.6K 0.19% 99
2021
Q2 		$677K Buy
1,212
+43
+4% +$21.8K 0.18% 103
2021
Q1 		$553K Buy
+1,169
New +$569K 0.16% 105
2020
Q2 		– Sell
-384
Closed -$209K – 246
2020
Q1 		$209K Buy
+384
New +$158K 0.03% 245

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HNP Capital's REGN Position: Q1 2023 in Review

HNP Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q1 2023, selling an estimated $18.1K and leaving 1,118 shares worth $919K. The position accounts for 0.26% of the portfolio, ranked #79.

HNP Capital first reported a position in REGN in Q1 2020 and has held it in 10 quarters since. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • HNP Capital held 1,118 shares of Regeneron Pharmaceuticals worth $919K as of Q1 2023.
  • HNP Capital sold 24 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $18.1K.
  • Regeneron Pharmaceuticals made up 0.26% of HNP Capital's portfolio in Q1 2023, its #79 holding.
  • HNP Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
  • 1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on HNP Capital's 13F filing for Q1 2023, filed 18 May 2023.